Persistent Urticarial Eruption in an Asthmatic Patient

Mukkamala, Raghu; Baban, Nawras; Krishnaswamy, Guha; Smith, John K.

doi:10.1016/s1081-1206(10)63333-9

Cited by 6 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The treatment of urticarial vasculitis, especially when skin‐limited, is less clear, with reports of beneficial treatment with NSAIDs, colchicine, hydroxychloroquine, dapsone, methotrexate, intramuscular gold therapy, azathioprine, and cyclophosphamide (11–14). Colchicine, dapsone, and antimalarials may be the most frequently tried therapies in skin‐predominant urticarial vasculitis.…”

Section: Syndromes Of Cutaneous Vasculitis With Minimal Extracutaneoumentioning

confidence: 99%

Therapy of leukocytoclastic (necrotizing) cutaneous vasculitis

Piette

2001

Dermatol Ther

View full text Add to dashboard Cite

There are multiple therapeutic options for cutaneous necrotizing vasculitis. The choice of the proper therapy is made more difficult by a variety of competing classification systems, and by a paucity of adequate clinical trials to assess efficacy of the most commonly used therapies. This article outlines an approach to therapy based on the diagnosis, the type of cutaneous involvement, the presence or absence of extracutaneous findings, and the known risks and benefits of currently available therapies for vasculitis.

show abstract

Section: Syndromes Of Cutaneous Vasculitis With Minimal Extracutaneoumentioning

confidence: 99%

Therapy of leukocytoclastic (necrotizing) cutaneous vasculitis

Piette

2001

Dermatol Ther

View full text Add to dashboard Cite

show abstract

“…Inflammatory processes that occur in asthma are summarized in Table 2 . Several inflammatory events occur in asthma, resulting in the observed pathophysiological (Figure 1 ) and clinical effects [ 1 - 3 ]. Th2-type T cells secreting a distinctive set of cytokines [such as interleukin (IL)-4, IL-5 and IL-13] play a pivotal role in asthma.…”

Section: Introductionmentioning

confidence: 99%

Severe asthma and the omalizumab option

Miller¹,

Krishnaswamy²,

Johnston³

et al. 2008

Clin Mol Allergy

Self Cite

View full text Add to dashboard Cite

Atopic diseases and asthma are increasing at a remarkable rate on a global scale. It is now well recognized that asthma is a chronic inflammatory disease of the airways. The inflammatory process in many patients is driven by an immunoglobulin E (IgE)-dependent process. Mast cell activation and release of mediators, in response to allergen and IgE, results in a cascade response, culminating in B lymphocyte, T lymphocyte, eosinophil, fibroblast, smooth muscle cell and endothelial activation. This complex cellular interaction, release of cytokines, chemokines and growth factors and inflammatory remodeling of the airways leads to chronic asthma. A subset of patients develops severe airway disease which can be extremely morbid and even fatal. While many treatments are available for asthma, it is still a chronic and incurable disease, characterized by exacerbation, hospitalizations and associated adverse effects of medications. Omalizumab is a new option for chronic asthma that acts by binding to and inhibiting the effects of IgE, thereby interfering with one aspect of the asthma cascade reviewed earlier. This is a humanized monoclonal antibody against IgE that has been shown to have many beneficial effects in asthma. Use of omalizumab may be influenced by the cost of the medication and some reported adverse effects including the rare possibility of anaphylaxis. When used in selected cases and carefully, omalizumab provides a very important tool in disease management. It has been shown to have additional effects in urticaria, angioedema, latex allergy and food allergy, but the data is limited and the indications far from clear. In addition to decreasing exacerbations, it has a steroid sparing role and hence may decrease adverse effects in some patients on high-dose glucocorticoids. Studies have shown improvement in quality of life measures in asthma following the administration of omalizumab, but the effects on pulmonary function are surprisingly small, suggesting a disconnect between pulmonary function, exacerbations and quality of life. Anaphylaxis may occur rarely with this agent and appropriate precautions have been recommended by the Food and Drug Administration (FDA). As currently practiced and as suggested by the new asthma guidelines, this biological agent is indicated in moderate or severe persistent allergic asthma (steps 5 and 6).

show abstract

Benefit of Colchicine in the Treatment of Schamberg's Disease

Geller¹

2000

Annals of Allergy, Asthma & Immunology

View full text Add to dashboard Cite

Persistent Urticarial Eruption in an Asthmatic Patient

Cited by 6 publications

References 19 publications

Therapy of leukocytoclastic (necrotizing) cutaneous vasculitis

Therapy of leukocytoclastic (necrotizing) cutaneous vasculitis

Severe asthma and the omalizumab option

Benefit of Colchicine in the Treatment of Schamberg's Disease

Contact Info

Product

Resources

About